再生元制药公司 REGN 深 沪
等待开盘 10-16 09:30:00 美东时间
576.42
+3.820
+0.67%
华盛通- 最 高584.865
- 今 开575.03
- 成交量 90.38万股
- 最 低 569.02
- 昨 收 572.60
- 总市值 622.53亿
- 52周最高 940.63
- 市盈率 静 15.04
- 换手率 0.84%
- 52周最低 475.6069
- 委 比 -54.21%
- 总股本 1.08亿
- 历史最高 1208.5599
- 量 比 0.73
- 振 幅 2.77%
- 历史最低 40.19
- 每 手 1
- 风险率 106.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
USA News Group News Commentary – Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development is acc...
10-15 21:11
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
Regeneron Pharmaceuticals announced new data from its Phase 3 C-POST trial at the 2025 ESMO Meeting, highlighting a patient-centric 6-week dosing regimen for Libtayo (cemiplimab) as adjuvant therapy for high-risk cutaneous squamous cell carcinoma (CSCC). The trial demonstrated similar efficacy, pharmacokinetics, and safety profiles between 3-week and 6-week dosing schedules. The new data support Libtayo's use in reducing recurrence risk for CSCC ...
10-15 11:00
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Citigroup Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $660
Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $650 to $660.
10-13 23:57
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
从这四个关键词，看全球药物研发管线的中国“成绩单”
随着国内医药创新的政策生态环境不断完善，创新药研发迎来快速发展，全球竞争力显著提升。笔者从药物管线存量、创新药管线增量、头部企业竞争等维度，分析总结近年中国医药...
10-13 09:42
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
Regeneron's DB-OTO gene therapy for otoferlin-related hearing loss shows promising results in the CHORD trial. 11 out of 12 participants experienced significant hearing improvements, with 3 achieving normal hearing. Those followed longer showed stable or continued improvement. Speech assessments demonstrated significant progress, including identifying words without visual cues. The therapy was well-tolerated with no serious adverse events linked ...
10-12 14:18
深度｜诺奖背后生物技术公司力量迅速崛起，科学家创业有何秘诀？
在做科研的时候，一定是挑专业领域里最难的问题去攻克，而在创办企业的时候，应该要挑最容易的那部分去做，这样才最有可能将科研成果转化为实际的经济收益。 诺贝...
10-12 14:06
特朗普宣布“史上最强药价谈判”：阿斯利康签署最惠国价格协议
（来源：药研网） 2025年10月10日，美国总统唐纳德·J·特朗普在白宫椭圆形办公室宣布，与阿斯利康（AstraZeneca）达成‘第二份最惠国价格协议’（...
10-11 17:12
